ATE297730T1 - Nasenspray enthaltend ondansetron-hydrochlorid - Google Patents

Nasenspray enthaltend ondansetron-hydrochlorid

Info

Publication number
ATE297730T1
ATE297730T1 AT02252717T AT02252717T ATE297730T1 AT E297730 T1 ATE297730 T1 AT E297730T1 AT 02252717 T AT02252717 T AT 02252717T AT 02252717 T AT02252717 T AT 02252717T AT E297730 T1 ATE297730 T1 AT E297730T1
Authority
AT
Austria
Prior art keywords
weight
antiemetic
ondansetron hydrochloride
cyclodextrin
beta
Prior art date
Application number
AT02252717T
Other languages
English (en)
Inventor
Jin Auh
Chang Hwan Kim
In Koo Chun
Original Assignee
Ahn Gook Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2002-0001758A external-priority patent/KR100434390B1/ko
Application filed by Ahn Gook Pharma Co Ltd filed Critical Ahn Gook Pharma Co Ltd
Application granted granted Critical
Publication of ATE297730T1 publication Critical patent/ATE297730T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02252717T 2001-04-20 2002-04-17 Nasenspray enthaltend ondansetron-hydrochlorid ATE297730T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20010021573 2001-04-20
KR10-2002-0001758A KR100434390B1 (ko) 2001-04-20 2002-01-11 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1h-이미다졸-1-일)메틸]-4h-카바졸-4-온을 유효성분으로 하는 비강분무용조성물

Publications (1)

Publication Number Publication Date
ATE297730T1 true ATE297730T1 (de) 2005-07-15

Family

ID=36217590

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02252717T ATE297730T1 (de) 2001-04-20 2002-04-17 Nasenspray enthaltend ondansetron-hydrochlorid

Country Status (6)

Country Link
US (1) US20030044356A1 (de)
EP (1) EP1250925B1 (de)
JP (1) JP4152118B2 (de)
AT (1) ATE297730T1 (de)
DE (1) DE60204620T2 (de)
ES (1) ES2244726T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328186D0 (en) * 2003-12-05 2004-01-07 West Pharm Serv Drug Res Ltd Intranasal compositions
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
US20060045850A1 (en) * 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
RU2009127890A (ru) * 2007-01-17 2011-02-27 Девирэкс Аг (Ch) Составы, содержащие циклодекстрины
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
EP2432467B1 (de) * 2009-05-20 2018-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin-5-ht3-rezeptor-antagonisten zur verwendung bei der behandlung von vestibulären läsionsstörungen
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
CA2846340A1 (en) * 2011-08-25 2013-02-28 Matthew J. D'onofrio Treatment of symptoms associated with female gastroparesis
DE102013001151A1 (de) 2013-01-24 2014-07-24 Merz Pharma Gmbh & Co. Kgaa Sprühbare flüssige Zubereitung zur insbesondere nasalen Anwendung mit erhöhter lokaler Verweilzeit
DE202013000748U1 (de) 2013-01-24 2013-02-19 Merz Pharma Gmbh & Co. Kgaa Sprühbare flüssige Zubereitung zur insbesondere nasalen Anwendung mit erhöhter lokaler Verweilzeit
PL2759290T3 (pl) 2013-01-24 2020-03-31 Merz Pharma Gmbh & Co. Kgaa Płynny preparat w aerozolu do stosowania donosowego z wydłużonym miejscowym czasem działania
US9050325B2 (en) * 2013-04-08 2015-06-09 Abdul Zahir Ondansetron nasal spray composition
US10736842B2 (en) * 2014-06-25 2020-08-11 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
US20160206610A1 (en) * 2015-01-20 2016-07-21 Xoc Pharmaceuticals, Inc. Methods for treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or acute emesis and/or delayed emesis
HRP20240453T1 (hr) 2016-04-14 2024-06-21 Sensorion (+)-azasetron za uporabu u liječenju poremećaja uha
EP3554489A4 (de) 2016-12-15 2020-06-17 Evoke Pharma, Inc. Behandlung von mässiger bis schwerer gastroparese
CN113559277B (zh) * 2018-01-11 2023-11-17 比卡生物科技(广州)有限公司 一种注射用卡巴他赛组合物及其制备方法
EP3827822B1 (de) 2018-07-25 2024-11-06 Bika Biotechnology (Guangzhou) Co., Ltd. Docetaxelzusammensetzung zur injektion und herstellungsverfahren dafür
GB202301322D0 (en) 2023-01-30 2023-03-15 Therakind Ltd Antiemetic pharmaceutical compositions for nasal delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU202108B (en) * 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5688955A (en) * 1996-03-08 1997-11-18 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
WO2000051582A2 (en) * 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
AU5397300A (en) * 1999-06-02 2000-12-28 Hexal Ag Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water
US6780825B2 (en) * 2001-02-06 2004-08-24 Playtex Products, Inc. Cleansing compositions with milk protein and aromatherapy

Also Published As

Publication number Publication date
EP1250925A2 (de) 2002-10-23
DE60204620T2 (de) 2006-05-11
JP4152118B2 (ja) 2008-09-17
EP1250925B1 (de) 2005-06-15
EP1250925A3 (de) 2003-11-26
DE60204620D1 (de) 2005-07-21
ES2244726T3 (es) 2005-12-16
US20030044356A1 (en) 2003-03-06
JP2002356424A (ja) 2002-12-13

Similar Documents

Publication Publication Date Title
DE60204620D1 (de) Nasenspray enthaltend Ondansetron-hydrochlorid
BR0003364A (pt) Composições farmacêuticas
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
ATE234634T1 (de) Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
ES2193208T3 (es) Nuevos derivados de quinuclidina y composicion farmaceutica que los contiene.
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
MXPA04000226A (es) Composiciones generadoras de mousse que contienen agentes de amonio cuaternario.
EA200400432A1 (ru) Производные мочевины
IS2310B (is) Nefholssamsetning úr rótigótíni
NO2010023I2 (no) Vernakalant eller et solvat eller farmasøytisk akseptabelt salt derav, herunder inkludert vernakalanthydroklorid
ATE271383T1 (de) Pulverformulierung zur inhalation
ATE376423T1 (de) Gelierende wässrige pharmazeutische zusammensetzungen
DE69635996D1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
SE0402762D0 (sv) Indazole sulphonamide derivatives
PT1230236E (pt) Composto com propriedades de libertacao de hormonas de crescimento
BR0212075A (pt) Combinações de substâncias ativas fungicidas
JP3846537B2 (ja) コンタクトレンズ用装着液
BR0013793A (pt) Medicamentos profiláticos e terapêuticos para doenças oftálmicas
PT992509E (pt) Novos derivados macrolidos
TW200501963A (en) Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
ATE273704T1 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
AU2002344454A1 (en) Percutaneous absorption preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one
JP5092138B2 (ja) コンタクトレンズ装着液
HU0102987D0 (en) Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1250925

Country of ref document: EP